David Leppert
Overview
Explore the profile of David Leppert including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
138
Citations
5006
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Disanto G, Schaedelin S, Oechtering J, Lorscheider J, Galbusera R, Finkener S, et al.
Mult Scler J Exp Transl Clin
. 2025 Feb;
11(1):20552173251315457.
PMID: 40017897
Background: Persistence to B cell depleting therapies (BCDT) like ocrelizumab and rituximab may be higher compared with other disease-modifying therapies (DMT) in multiple sclerosis (MS). Clinical trials directly comparing these...
2.
Oechtering J, Schaedelin S, Stein K, Maceski A, Melie-Garcia L, Benkert P, et al.
Neurol Neuroimmunol Neuroinflamm
. 2025 Jan;
12(2):e200361.
PMID: 39752618
Background And Objectives: Levels of activated complement proteins in the CSF are increased in people with multiple sclerosis (MS) and are associated with clinical disease severity. In this study, we...
3.
Benkert P, Maceski A, Schaedelin S, Oechtering J, Zadic A, Vilchez Gomez J, et al.
Ann Neurol
. 2024 Oct;
PMID: 39411917
Objective: To investigate the longitudinal dynamics of serum glial fibrillary acidic protein (sGFAP) and serum neurofilament light chain (sNfL) levels in people with multiple sclerosis (pwMS) under B-cell depleting therapy...
4.
Janiaud P, Zecca C, Salmen A, Benkert P, Schadelin S, Orleth A, et al.
Trials
. 2024 Sep;
25(1):607.
PMID: 39261900
Background: Treatment decisions for persons with relapsing-remitting multiple sclerosis (RRMS) rely on clinical and radiological disease activity, the benefit-harm profile of drug therapy, and preferences of patients and physicians. However,...
5.
Greselin M, Lu P, Melie-Garcia L, Ocampo-Pineda M, Galbusera R, Cagol A, et al.
Bioengineering (Basel)
. 2024 Aug;
11(8).
PMID: 39199815
The detection of contrast-enhancing lesions (CELs) is fundamental for the diagnosis and monitoring of patients with multiple sclerosis (MS). This task is time-consuming and suffers from high intra- and inter-rater...
6.
Khalil M, Teunissen C, Lehmann S, Otto M, Piehl F, Ziemssen T, et al.
Nat Rev Neurol
. 2024 Apr;
20(5):269-287.
PMID: 38609644
Neurofilament proteins have been validated as specific body fluid biomarkers of neuro-axonal injury. The advent of highly sensitive analytical platforms that enable reliable quantification of neurofilaments in blood samples and...
7.
Kuhle J, Leppert D, Comi G, De Stefano N, Kappos L, Freedman M, et al.
Ther Adv Neurol Disord
. 2024 Apr;
17:17562864241239101.
PMID: 38560407
Background: In REFLEX, subcutaneous interferon beta-1a (sc IFN β-1a) delayed the onset of multiple sclerosis (MS) in patients with a first clinical demyelinating event (FCDE). Objectives: This analysis aimed to...
8.
Oechtering J, Stein K, Schaedelin S, Maceski A, Orleth A, Meier S, et al.
Neurol Neuroimmunol Neuroinflamm
. 2024 Feb;
11(2):e200212.
PMID: 38354323
Background And Objectives: Histopathologic studies have identified immunoglobulin (Ig) deposition and complement activation as contributors of CNS tissue damage in multiple sclerosis (MS). Intrathecal IgM synthesis is associated with higher...
9.
Cagol A, Benkert P, Melie-Garcia L, Schaedelin S, Leber S, Tsagkas C, et al.
Neurology
. 2024 Jan;
102(1):e207768.
PMID: 38165377
Background And Objectives: Progression independent of relapse activity (PIRA) is a crucial determinant of overall disability accumulation in multiple sclerosis (MS). Accelerated brain atrophy has been shown in patients experiencing...
10.
Abdelhak A, Benkert P, Schaedelin S, Boscardin W, Cordano C, Oechtering J, et al.
JAMA Neurol
. 2023 Nov;
80(12):1317-1325.
PMID: 37930670
Importance: Mechanisms contributing to disability accumulation in multiple sclerosis (MS) are poorly understood. Blood neurofilament light chain (NfL) level, a marker of neuroaxonal injury, correlates robustly with disease activity in...